|
|
Post by JHam on Jul 16, 2014 14:15:55 GMT
Opexa Therapeutics, Inc. (Opexa) is a biopharmaceutical company. The Company is engaged in developing personalized cellular therapies with the potential to treat illnesses, including multiple sclerosis (MS). These therapies are based on its T-cell technology. The Company’s core product candidate, Tovaxin, is a personalized T-cell therapeutic vaccine licensed from Baylor College of Medicine, which is in clinical development for the treatment of MS. Tcelna is a T-cell immunotherapy in Phase IIb clinical development for the treatment of patients with secondary progressive MS (SPMS).Tcelna is a personalized therapy that is specifically tailored to each patient’s disease profile. The TERMS study was a multi-center, randomized, double blind, placebo-controlled trial in 150 patients with RRMS or high risk Clinically Isolated Syndrome.
|
|
|
|
Post by Yelk on Jan 7, 2015 3:57:05 GMT
www.youtube.com/watch?v=u3Y92fh-Ccw&feature=youtu.beI have been doing some research on this company looking for potential catalysts. My Research indicated news 2h 2016 and results so far at week 52 Tcelna is 30-40% reduction of MRTA, so far decent results as far as I'm concerned but I'm not overly familiar yet so don't take my word for it, do DD.  -52 week low -Low market share with huge market potential -Fast tracked FDA -II Trial in progress -All analyst ratings I've seen so far is strong buy and high TP -100% insider trades are buys in last year -This company is really one of the only companies that CEO quote "tries to kill the conductor of the orchestra" and attempts to right the heart by selecting t cells and removing them A second major catalyst is opx 212 which will be getting updates for the majority of 2015 as we go along. One issue I noticed and am not sure of its complications as I'm not a veteran investor: In accordance with listing rule 5810(c)(3)(A), the Company has 180 calendar days, or until June 3, 2015, to regain compliance with the minimum bid price rule. To regain compliance, the closing bid price of the Company’s common stock must be at least $1.00 per share for a minimum of ten consecutive business days (or such longer period of time as the NASDAQ staff may require in some circumstances, but generally not more than 20 consecutive business days) before June 3, 2015. This seems like a risky and possibly pointless investment but the potential billion market should this be approved could be a long investment with a small amount (but then again what biotech company isn't). I listened to several webcasts. Feel free to post thoughts on this and opinions of my research should you do some yourself.
|
|
